{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:39:33Z","timestamp":1787247573314,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107133","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:58:12Z","timestamp":1773161892000},"page":"107133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Neutropenia after ocrelizumab treatment in patients with multiple sclerosis: A single-centre case series and systematic review of literature"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9607-3460","authenticated-orcid":false,"given":"Joana Almada","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Leit\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107133_bib0001","article-title":"A case of late-onset neutropenia in relapsing-remitting multiple sclerosis following Ocrelizumab therapy","volume":"16","author":"Alabdulqader","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.msard.2026.107133_bib0002","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nrl.2021.01.010","article-title":"Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab","volume":"38","author":"Alba Su\u00e1rez","year":"2023","journal-title":"Neurologia Engl. Ed."},{"key":"10.1016\/j.msard.2026.107133_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102155","article-title":"Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab","volume":"43","author":"Auer","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107133_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1941874420936438","article-title":"Severe delayed-onset neutropenia induced by Ocrelizumab","volume":"11","author":"Baird-Gunning","year":"2021","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.msard.2026.107133_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105400","article-title":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","volume":"82","author":"Baker","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107133_bib0006","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/13524585231206218","article-title":"Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab","volume":"30","author":"Beigneux","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107133_bib0007","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107133_bib0008","article-title":"047 Rare late onset neutropenia in a patient with multiple sclerosis treated with ocrelizumab and review of literature","volume":"3","author":"Dal","year":"2021","journal-title":"BMJ Neurol. Open."},{"key":"10.1016\/j.msard.2026.107133_bib0009","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neurop.2021.03.017","article-title":"Neutropenia t\u00f3xica tras ocrelizumab sin recurrencias posteriores tras continuar el tratamiento","volume":"1","author":"Gascon-Gimenez","year":"2021","journal-title":"Neurol. Perspect."},{"key":"10.1016\/j.msard.2026.107133_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104015","article-title":"Ocrelizumab-related neutropenia: effects of age, sex and bodyweight using the FDA adverse event reporting system (FAERS)","author":"Hammer","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107133_bib0011","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107133_bib0012","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00115-023-01507-2","article-title":"Ocrelizumab-associated severe neutropenia: an underestimated complication of treatment of multiple sclerosis with anti-CD20 antibodies?","volume":"94","author":"Hess","year":"2023","journal-title":"Nervenarzt"},{"key":"10.1016\/j.msard.2026.107133_bib0013","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2298\/SARH211216042J","article-title":"Ocrelizumab associated late-onset neutropenia in the patient with multiple sclerosis: case report and literature review","volume":"150","author":"Jovi\u0107evi\u0107","year":"2022","journal-title":"Srp. Arh. Celok. Lek."},{"key":"10.1016\/j.msard.2026.107133_bib0014","article-title":"Myeloid maturation arrest and severe late-onset neutropenia following ocrelizumab therapy in a patient with multiple sclerosis: a case report and review of the literature","volume":"1","author":"Kermode","year":"2021","journal-title":"Neuroimmunol. Rep."},{"key":"10.1016\/j.msard.2026.107133_bib0015","article-title":"Late-onset neutropenia following anti-CD20 therapies in multiple sclerosis and neuromyelitis optica spectrum disorders: a report on two patients","volume":"2","author":"Lim","year":"2022","journal-title":"Neuroimmunol. Rep."},{"key":"10.1016\/j.msard.2026.107133_bib0016","article-title":"Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report","author":"Maniscalco","year":"2021","journal-title":"Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2026.107133_bib0017","article-title":"Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient","author":"Marrodan","year":"2021","journal-title":"Neurol. Sci. Off J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2026.107133_bib0018","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/25785826.2021.1952543","article-title":"B-cell depletion therapy for multiple sclerosis","volume":"45","author":"Miyazaki","year":"2022","journal-title":"Immunol. Med."},{"key":"10.1016\/j.msard.2026.107133_bib0019","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/WNL.54.11.2147","article-title":"Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor","volume":"54","author":"Openshaw","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107133_bib0020","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.107133_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.4919","article-title":"Rapid onset drug induced neutropenia associated with Ocrelizumab in multiple sclerosis (4919)","volume":"94","author":"Pala","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107133_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105147","article-title":"Neutropaenia complications from Ocrelizumab and Rituximab treatment","volume":"81","author":"Pang","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107133_bib0023","first-page":"1025","article-title":"Neutropaenia complicating anti-CD20 therapy in multiple sclerosis: a retrospective review of cases in South-East London and Kent","volume":"30","author":"Paranavitane","year":"2024","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107133_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: a case report","volume":"10","author":"Rauniyar","year":"2022","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.msard.2026.107133_bib0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neurol.2021.06.007","article-title":"Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: a prospective study","volume":"178","author":"Rigal","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2026.107133_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104090","article-title":"Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: a retrospective case series and a systematic review of reported cases","volume":"68","author":"Rossi","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107133_bib0027","first-page":"631","article-title":"Ocrelizumab-induced neutropenia in people with multiple sclerosis: a single-centre study","volume":"30","author":"Sartori","year":"2024","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107133_bib0028","article-title":"Late onset recurrent neutropenia following ocrelizumab therapy in multiple sclerosis","volume":"93","author":"Talaei","year":"2022","journal-title":"J. Neurol. Neurosurg. Amp.; Psychiatry"},{"key":"10.1016\/j.msard.2026.107133_bib0029","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1212\/WNL.0000000000206160","article-title":"Late-onset severe neutropenia in a patient with relapsing remitting multiple sclerosis treated with Ocrelizumab (P10-6.010)","volume":"102","author":"Tauro","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107133_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116603","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature","author":"Zanetta","year":"2020","journal-title":"J. Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:20:44Z","timestamp":1781526044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"alternative-id":["S2211034826001690"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107133","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutropenia after ocrelizumab treatment in patients with multiple sclerosis: A single-centre case series and systematic review of literature","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107133"}}